Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease

Zhao,Qing; Cai,Dingfang; Bai,Yu

doi:10.3892/ijmm.2013.1450

Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease

Authors:
- Qing Zhao
- Dingfang Cai
- Yu Bai
View Affiliations

Affiliations: Department of Neurology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China, Laboratory of Neurological Research of the Institute of Integrative Medicine, Shanghai, P.R. China
Published online on: July 18, 2013 https://doi.org/10.3892/ijmm.2013.1450
Pages: 883-891

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The monoamine oxidase type-B (MAO‑B) inhibitor, selegiline, is often recommended as a first-line treatment for Parkinson's disease (PD) and has been shwon to possess neuroprotective effects. The aim of the present study was to determine whether selegiline increases the levels of the neurotrophic factors (NTFs), glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF), and whether it rescues motor dysfunction and the loss of dopaminergic neurons in mice with 1-methyl-4‑phenyl‑1,2,3,6‑tetrahydropyridine (MPTP)-induced lesions. We found that the oral administration of selegiline (1.0 mg/kg/day for 14 days) successfully suppressed the MPTP‑induced reduction of nigral dopaminergic neurons and striatal fibers (192.68 and 162.76% of MPTP‑exposed animals, respectively; both P<0.001). Moreover, improvements in gait dysfunction were observed after 7 and 14 days of a low dose of selegiline that is reported not to inhibit MAO‑B. Furthermore, there was a significant increase in GDNF and BDNF mRNA (2.10 and 2.75-fold) and protein levels (143.53 and 157.05%) in the selegiline‑treated mice compared with the saline‑treated MPTP‑exposed mice. In addition, the Bax/Bcl‑2 gene and protein expression ratios were significantly increased in the MPTP-exposed mice, and this effect was reversed by selegiline. Correlation analysis revealed that gait measurement and GDNF/BDNF levels positively correlated with the number of dopaminergic neurons. These findings demonstrate that selegiline has neurorescue effects that are possibly associated with the induction of NTFs and anti-apoptotic genes.

View Figures

View References

1	Lees AJ, Hardy J and Revesz T: Parkinson’s disease. Lancet. 373:2055–2066. 2009.
2	Stocchi F, Vacca L, Grassini P, et al: Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology. 67:S24–S29. 2006. View Article : Google Scholar : PubMed/NCBI
3	Bar-Am O, Weinreb O, Amit T and Youdim MB: The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem. 112:1131–1137. 2010. View Article : Google Scholar : PubMed/NCBI
4	Olanow CW, Hauser RA, Jankovic J, et al: A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 23:2194–2201. 2008.
5	Weinreb O, Mandel S, Bar-Am O, et al: Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer’s disease drugs. Neurotherapeutics. 6:163–174. 2009.PubMed/NCBI
6	Chen JJ and Ly AV: Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson’s disease. Am J Health Syst Pharm. 63:915–928. 2006.
7	Magyar K, Pálfi M, Jenei V and Szöko E: Deprenyl: from chemical synthesis to neuroprotection. J Neural Transm Suppl. 143–156. 2006. View Article : Google Scholar : PubMed/NCBI
8	Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S and Youdim MB: Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J Neural Transm Suppl. 457–465. 2006. View Article : Google Scholar
9	Youdim MB, Maruyama W and Naoi M: Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Drugs Today (Barc). 41:369–391. 2005. View Article : Google Scholar
10	Youdim MB and Tipton KF: Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson’s disease. Parkinsonism Relat Disord. 8:247–253. 2002.PubMed/NCBI
11	Hara MR, Thomas B, Cascio MB, et al: Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc Natl Acad Sci USA. 103:3887–3889. 2006. View Article : Google Scholar : PubMed/NCBI
12	Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB and Naoi M: Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 24:675–682. 2002.
13	Maruyama W, Nitta A, Shamoto-Nagai M, et al: N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int. 44:393–400. 2004. View Article : Google Scholar
14	Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O and Youdim MB: Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 18:1471–1473. 2004.PubMed/NCBI
15	Sagi Y, Mandel S, Amit T and Youdim MB: Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis. 25:35–44. 2007. View Article : Google Scholar
16	Zhu W, Xie W, Pan T, et al: Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem. 105:1970–1978. 2008. View Article : Google Scholar
17	Jackson-Lewis V and Przedborski S: Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc. 2:141–151. 2007.
18	Perier C, Bové J, Wu DC, et al: Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson’s disease. Proc Natl Acad Sci USA. 104:8161–8166. 2007.
19	Fernagut PO, Diguet E, Labattu B and Tison F: A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods. 113:123–130. 2002. View Article : Google Scholar : PubMed/NCBI
20	Fleming SM, Salcedo J, Fernagut PO, et al: Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci. 24:9434–9440. 2004. View Article : Google Scholar : PubMed/NCBI
21	Tillerson JL, Caudle WM, Reverón ME and Miller GW: Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Exp Neurol. 178:80–90. 2002. View Article : Google Scholar
22	Paxinos G and Franklin KBJ: The Mouse Brain in Stereotaxic Coordinates. 4th edition. Elsevier Academic Press; San Diego: 2012
23	He XJ, Yamauchi H, Uetsuka K and Nakayama H: Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson’s disease. Neurotoxicology. 29:413–420. 2008.PubMed/NCBI
24	Yokoyama H, Takagi S, Watanabe Y, Kato H and Araki T: Role of reactive nitrogen and reactive oxygen species against MPTP neurotoxicity in mice. J Neural Transm. 115:831–842. 2008. View Article : Google Scholar : PubMed/NCBI
25	Kuhn K, Wellen J, Link N, Maskri L, Lübbert H and Stichel CC: The mouse MPTP model: gene expression changes in dopaminergic neurons. Eur J Neurosci. 17:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
26	West MJ and Gundersen HJ: Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol. 296:1–22. 1990. View Article : Google Scholar : PubMed/NCBI
27	Wu DC, Jackson-Lewis V, Vila M, et al: Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 22:1763–1771. 2002.PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. methods. 25:402–408. 2001.
29	Matsunaga W, Isobe K and Shirokawa T: Involvement of neurotrophic factors in aging of noradrenergic innervations in hippocampus and frontal cortex. Neurosci Res. 54:313–318. 2006. View Article : Google Scholar : PubMed/NCBI
30	Novikova L, Garris BL, Garris DR and Lau YS: Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson’s disease. Neuroscience. 140:67–76. 2006.PubMed/NCBI
31	Blin O, Ferrandez AM and Serratrice G: Quantitative analysis of gait in Parkinson patients: increased variability of stride length. J Neurol Sci. 98:91–97. 1990. View Article : Google Scholar : PubMed/NCBI
32	Muller T: Drug therapy in patients with Parkinson’s disease. Transl Neurodegener. 1:102012.
33	Lewitt PA: MAO-B inhibitor know-how: back to the pharm. Neurology. 72:1352–1357. 2009. View Article : Google Scholar
34	Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson’s disease. Arch Neurol. 46:1052–1060. 1989.
35	Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol. 59:1937–1943. 2002. View Article : Google Scholar : PubMed/NCBI
36	Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F and Tolosa E; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med. 361:1268–1278. 2009.
37	Ansari KS, Yu PH, Kruck TP and Tatton WG: Rescue of axotomized immature rat facial motoneurons by R(−)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J Neurosci. 13:4042–4053. 1993.
38	Sharma SK, Carlson EC and Ebadi M: Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP⁺)-induced apoptosis in SK-N-SH neurons. J Neurocytol. 32:329–343. 2003. View Article : Google Scholar : PubMed/NCBI
39	Tatton WG, Chalmers-Redman RM, Ju WJ, et al: Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther. 301:753–764. 2002. View Article : Google Scholar : PubMed/NCBI
40	Holschneider DP, Chen K, Seif I and Shih JC: Biochemical, behavioral, physiologic, and neurodevelopmental changes in mice deficient in monoamine oxidase A or B. Brain Res Bull. 56:453–462. 2001. View Article : Google Scholar : PubMed/NCBI
41	Weinreb O, Amit T, Bar-Am O and Youdim MB: Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann NY Acad Sci. 1122:155–168. 2007. View Article : Google Scholar : PubMed/NCBI
42	Ebadi M, Sharma S, Shavali S and El Refaey H: Neuroprotective actions of selegiline. J Neurosci Res. 67:285–289. 2002. View Article : Google Scholar : PubMed/NCBI
43	Levy OA, Malagelada C and Greene LA: Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis. 14:478–500. 2009.
44	Tanaka K, Asanuma M and Ogawa N: Molecular basis of anti-apoptotic effect of immunophilin ligands on hydrogen peroxide-induced apoptosis in human glioma cells. Neurochem Res. 29:1529–1536. 2004. View Article : Google Scholar
45	Meredith GE and Kang UJ: Behavioral models of Parkinson’s disease in rodents: a new look at an old problem. Mov Disord. 21:1595–1606. 2006.
46	Patel M, Mao L, Wu B and Vandevord PJ: GDNF-chitosan blended nerve guides: a functional study. J Tissue Eng Regen Med. 1:360–367. 2007. View Article : Google Scholar : PubMed/NCBI
47	Piquilloud G, Christen T, Pfister LA, Gander B and Papaloïzos MY: Variations in glial cell line-derived neurotrophic factor release from biodegradable nerve conduits modify the rate of functional motor recovery after rat primary nerve repairs. Eur J Neurosci. 26:1109–1117. 2007. View Article : Google Scholar
48	Willson ML, McElnea C, Mariani J, Lohof AM and Sherrard RM: BDNF increases homotypic olivocerebellar reinnervation and associated fine motor and cognitive skill. Brain. 131:1099–1112. 2008. View Article : Google Scholar : PubMed/NCBI
49	Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R and Young B: Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg. 102:216–222. 2005. View Article : Google Scholar